Your Cart ( 1 Item )

• Apremilast for the Treatment of Mild-to-Moderate Hidradenitis Suppurativa in a Prospective, Open-Label, Phase 2 Study
  February 2019 | Volume 18 | Issue 2 | Original Article | 170 | Copyright © February 2019
  Franz R. Kerdel DO, Fabio A. Azevedo CCRC, Christina Kerdel Don PA-C MCMSc, Frank A. Don DO, Gabriella Fabbrocini MD, Francisco A. Kerdel, BSc MBBS
  You will have 48 hours to download the full-text PDF

  Price

  24.95

  Term

  48 Hrs